FDA proposes excluding tirzepatide from the 503B bulks list
If finalised, outsourcing facilities would lose a pathway for compounding at scale.
Released: · Last reviewed:
If finalised, outsourcing facilities would lose a pathway for compounding at scale.
The proposal covers semaglutide, tirzepatide and liraglutide. Outsourcing facilities compound from bulk substances under that list; exclusion would remove a pathway for producing these molecules at scale outside patient-specific prescriptions.
This is a proposal, not a final rule, and coverage frequently conflates the two. Patient-specific compounding under 503A is a separate pathway and is not what the proposal addresses.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
Month-to-month all-in prices at 10 mg among the programs we track start at $129 (Eden Health, read October 15, 2026; NexLife charges the same as of November 6, 2026). Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.